Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 06, 2020 10:00 ET | Source: BioIntervene Inc.

BioIntervene Announces $30 Million Series A Financing

− Proceeds to advance portfolio of selective A3 adenosine receptor agonists through human proof-of-concept studies − − Company appoints Dr. Charles Cohen as Chief Scientific Officer − SAN DIEGO,...